New Xolair abstract

[Guest guest]

Thank you so much for sharing this with the group! I'll bet the

decrease in esinophils and the effect on inflammation described

accounts for the significant decrease in my allergic rhinitis

symptoms (which were very severe), something that has really

improved my life.

Addy

>

> Clin Exp Allergy. 2005 Apr;35(4):408-16.Related Articles, Links

>

>

> Anti-immunoglobulin E treatment with omalizumab in allergic

diseases: an

> update on anti-inflammatory activity and clinical efficacy.

>

> Holgate ST, Djukanovic R, Casale T, Bousquet J.

>

> Southampton General Hospital, Southampton, UK.

>

> Summary Omalizumab is a humanized monoclonal anti-IgE antibody

developed for

> the treatment of allergic disease, with established efficacy in

patients with

> moderate-to-severe allergic asthma and in patients with

intermittent

> (seasonal) and persistent (perennial) allergic rhinitis (AR).

Omalizumab is known to

> result in a marked reduction in serum levels of free IgE and down-

regulation of

> IgE receptors on circulating basophils. Recent work has shed

further light on

> its mechanism of action, showing significant and profound

reductions in tissue

> (nasal and bronchial) eosinophils and in bronchial IgE(+) cells

(mast cells),

> as well as T cells and B cells. Omalizumab treatment was also

shown to be

> associated with down-regulation of IgE receptors on circulating

(precursor)

> dendritic cells, suggesting that blocking IgE may inhibit more

chronic aspects of

> allergic inflammation involving T cell activation. Further work

with omalizumab

> demonstrated it to have important benefits in patients with poorly

controlled

> asthma despite high-dose inhaled corticosteroid therapy, and

analysis of

> clinical data suggests that the patients who are the

best 'responders' to anti-IgE

> treatment are those with asthma at the more severe end of the

spectrum.

> Notably, systemic anti-IgE therapy with omalizumab has been shown

to improve

> symptoms, quality of life and disease control (asthma

exacerbations) in patients

> with concomitant asthma and persistent AR. These impressive

clinical data and the

> studies elucidating the anti-inflammatory profile of omalizumab

also serve to

> emphasize the fundamental importance of IgE in the pathogenesis of

allergic

> diseases.

>

>

>

[Guest guest]

Thought this might be of interest.

--Meryl

J Allergy Clin Immunol. 2005 Mar;115(3):459-65.Related Articles, Links

The anti-inflammatory effects of omalizumab confirm the central role of IgE

in allergic inflammation.

Holgate S, Casale T, Wenzel S, Bousquet J, Deniz Y, Reisner C.

RCMB Research Division, Southampton General Hospital, United Kingdom.

sth@...

Anti-IgE therapy with omalizumab reduces serum levels of free IgE and

downregulates expression of IgE receptors (Fc epsilonRI) on mast cells and

basophils. In the airways of patients with mild allergic asthma, omalizumab

reduces Fc epsilonRI+ and IgE+ cells and causes a profound reduction in

tissue eosinophilia, together with reductions in submucosal T-cell and

B-cell numbers. In patients with seasonal allergic rhinitis, omalizumab

inhibits the allergen-induced seasonal increases in circulating and tissue

eosinophils. Omalizumab decreases Fc epsilonRI expression on circulating

dendritic cells, which might lead to a reduction in allergen presentation,

T(H)2 cell activation, and proliferation. As a systemic anti-IgE agent,

omalizumab has demonstrated clinical efficacy in patients with moderate and

severe allergic asthma and in those with seasonal and perennial allergic

rhinitis, as well as in patients with concomitant allergic asthma and

allergic rhinitis. The anti-inflammatory effects

of omalizumab at different sites of allergic inflammation and the clinical

benefits of anti-IgE therapy in patients with allergic asthma and allergic

rhinitis emphasize the fundamental importance of IgE in allergic

inflammation.